Company Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.
The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology.
Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme.
The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019.
Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 1990 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Brian Culley |
Contact Details
Address: 2173 Salk Avenue, Suite 200 Carlsbad, California 92008 United States | |
| Phone | 442 287 8990 |
| Website | lineagecell.com |
Stock Details
| Ticker Symbol | LCTX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000876343 |
| CUSIP Number | 53566P109 |
| ISIN Number | US53566P1093 |
| Employer ID | 94-3127919 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rami Skaliter Ph.D. | Chief Executive Officer of Cell Cure Neurosciences |
| William Annett MBA | President and Chief Executive Officer of OncoCyte Corporation |
| Brian M. Culley M.A., M.B.A. | Chief Executive Officer, President and Director |
| Jill Ann Howe | Chief Financial Officer and Principal Financial and Accounting Officer |
| George A. Samuel III, J.D. | General Counsel and Company Secretary |
| Ioana C. Hone | Director of Investor Relations |
| Dr. Charlotte Hubbert Ph.D. | Vice President of Corporate Development |
| Brandi L. Roberts CPA, M.B.A. | Consultant |
| Alexandra Hernandez | Senior Director of Finance and Controller |
| Dr. Harold D. Waitz | Vice President of Regulatory Affairs and Quality Control |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 9, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 21, 2024 | 424B5 | Filing |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 8, 2024 | 10-Q | Quarterly Report |